Skip to content
DataLookout
Menu

CY-MET-RICNCT06252870

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 18, 2027 to Oct 18, 2029
    • Eligibility criteria expanded, about 29 words
    • Study completion pushed from Jul 18, 2028 to Jul 18, 2030
    • Secondary endpoints: details revised at 3 of 13 entries
  2. Minor Site details revised at 1 of 3 sitesv4
  3. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 3
    • Primary completion date: Sep 15, 2027 to Oct 18, 2027
    • Study completion date: May 15, 2028 to Jul 18, 2028
    • Start date changed from estimate of May 15, 2024 to Jul 18, 2024
  4. Notable Eligibility criteria expanded, about 50 words
    • Primary endpoint revised
    • Enrollment target: 60 to 82
    • Secondary endpoints: 12 to 13
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
Timeframe: Post-transplant through study completion, an average of 1 year

Secondary (13)

Incidence of engraftment
Overall survival (OS)
Disease-free survival (DFS)
GVHD and relapse-free survival (GRFS)
Incidence of acute GVHD grade 2-4
Show 8 moreShow less
Incidence of chronic GVHD
Incidence of corticoresistant acute GVHD
Incidence of non-relapse mortality (NRM)
Incidence of relapse
Chimerism
Immune reconstitution
Grade 3 and 4 post-transplant adverse events
Incidence of viral, bacteriological, fungal and parasitic infections

Arms and interventions

(CLO)-BALTIMOREExperimental

BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY

TBFActive comparator

Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY

Drugs: Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine, Cycophosphamide, Anti-Thymoglobulin, Clofarabine, Thiotepa, Busulfan

Radiation: total body irradiation

Other: hematopoietic stem cells, Graft nuclear cells, Donor Lymphocytes Injection

Sites

3 sites in 1 country